Explore more publications!

Healthcare Wire Texas: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthcare Wire Texas.

Press releases published on October 14, 2025

Aligos Therapeutics to Present at the H.C. Wainwright Liver Disease Conference
LB Pharmaceuticals Appoints James Rawls, Pharm.D., as Senior Vice President of Regulatory Affairs
FibroBiologics to Present at the 2025 ThinkEquity Conference
Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research
Profound Medical to Participate in the Stifel 2025 Healthcare Conference
As "Uptober" Ignites Crypto Market, Bonk, Inc. Revs Up Its Revenue-Generating Engine
Flare Therapeutics to Present FX-909 Phase 1A Data in Oral Presentation at Upcoming AACR-NCI-EORTC International Conference
IMUNON to Present Phase 3 Ovarian Cancer Study of IMNN-001 at ESMO Congress
Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc.
4DMT to Participate in Chardan's 9th Annual Genetic Medicines Conference
SpyGlass Pharma’s Novel BIM-IOL System Demonstrated a Statistically Significant Reduction in Mean IOP at 24 Months
Confluent Health Strengthens National Network with Addition of Commonwealth Hand & Physical Therapy
Myriad Genetics Adds F8, FXN Genes to Foresight Universal Plus Panel
NuCana Announces Encouraging Data for NUC-3373 in Combination with Anti-PD-1 Therapy
Amarin and HLS Therapeutics Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular Congress
Halda Therapeutics Announces Oral Plenary Presentation on HLD-0915 Clinical Data in Metastatic Castration-Resistant Prostate Cancer (mCRPC) at 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics on October 24, 2025
Corbus Pharmaceuticals to Present CRB-701 Phase 1/2 Data at ESMO 2025
Ashvattha Therapeutics Appoints Ophthalmology Veteran Robert J. Dempsey as Interim CEO Following Positive Phase 2 Results and FDA Alignment on Pivotal Program
Fate Therapeutics Expands Leadership Team with Appointment of Kamal Adawi as Chief Financial Officer
Tr1X Announces FDA Clearance of IND Application for TRX319, a First-in-Class Allogeneic CAR-Tr1 Treg Cell Therapy for Progressive Multiple Sclerosis, and $50 Million in Additional Financing

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions